Aziyo Biologics Inc., of Silver Spring, Md., said it launched Ostegro, an allograft bone matrix that supports new bone growth in orthopedic surgical procedures such as spinal fusion, hip reconstruction and bone fractures. Read More
Pulmatrix Inc., of Lexington, Mass., has filed to raise up to $20 million by offering up to 8.06 million common units, consisting of one share of common stock and one warrant to purchase one share. Read More
HONG KONG – Ever since the Hong Kong Stock Exchange (HKEX) announced plans to welcome pre-revenue biopharmaceutical startups, interest in going public here has spiked among early stage firms across Greater China. Listing in Hong Kong would open an avenue to new funds raised through this major stock market. Read More
The FDA launched its regenerative medicine advanced therapy (RMAT) designation program, which stemmed from the 21st Century Cures Act, roughly one year ago. By now, at least 43 companies have applied for the new designation with more than a dozen recipients who can attest to the enhanced regulatory access and cooperation under the program. Read More
AMSTERDAM – Secarna Pharmaceuticals GmbH & Co. KG, an early stage German firm, is giving a new lease of life to an old European antisense technology which will soon lose patent protection. The Marburg-based firm was formed in 2015, but has flown under the radar until recently. It was among the young contenders setting out their stall at the recent BIO-Europe Spring meeting. Read More
Biopharmaceutical companies had no difficulty attracting capital in 2017. In fact, they raised $52 billion – an amount that places the year solidly in second place in terms of annual totals generated by the industry. Read More
Clarivate Analytics Chief Scientific Officer Richard Harrison told BioWorld that the record number of would-be blockbusters in the firm's "Drugs to Watch" report for 2018 signals that "changes the industry made 10 years ago are really starting to pay off." Read More
Nearly halfway through the year, the U.S. House voted 256-167 Thursday to pass a $1.3 trillion omnibus spending bill to fund the federal government for fiscal 2018. Read More
Vital Therapies Inc., of San Diego, said the VTL-308 phase III trial of Elad, its extracorporeal human allogeneic cellular liver therapy, reached its enrollment target of 150 participants. Read More
